Lexaria Bioscience (LEXX) has received 2 new international patents. This now brings Lexaria’s total worldwide patent portfolio to 50. Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria’s intellectual property protection for the use of its DehydraTECH enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044. Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.